



CLL Patient and Caregiver Educational Forum

In partnership with MD Anderson and the Leukemia & Lymphoma Society (LLS), the CLL Society invites you to attend our informational CLL patient educational forum. Featured speakers will present the very latest advances in CLL research, clinical trials, treatment options, patient perspectives, and tips to become an effective self-advocate.

Date: Saturday, March 16, 2019 Location: The University of Texas MD Anderson Texas

Medical Center

 Time:
 8:00 AM – 8:30 AM
 Registration
 Main Building R11.1100
 Rooms 1-2, 7-8

 8:30 AM – 12:00 PM
 Program
 1515 Holcombe Blvd., Houston TX 77030

AGENDA		
8:30 AM	Welcome and Introductions	Brian Koffman, MD
8:40 AM	CLL Diagnosis and Early Management	Philip Thompson, MD
9:10 AM	CLL Treatments – Latest from ASH 2018 and Local Clinical Trials	William Wierda, MD
9:40 AM	Vaccinations, Other Cancer Screening, Growth Factors & IVIG	Jill Vershel, MS, PA-C
10:10 AM	Q&A	Thompson, Wierda
10:35 AM	Break	
10:50 AM	Services of The Leukemia and Lymphoma Society	Erika Pomares, LMSW
11:10 AM	Being Your Own Advocate/Smart Patients Get Smart Care™	Brian Koffman, MD
11:40 AM	Why Join the Houston CLL Society Support and Education Group	Maitine Rivera Susan Smith
11:50 AM	Q&A and Conclusion	



William Wierda, MD, PhD MD Anderson



Philip Thompson, MB, BS MD Anderson



Jill Vershel, MS, PA-C MD Anderson



Erika Pomares, LMSW Sr. Patient Access Manager The Leukemia & Lymphoma Society



Brian Koffman, MD CLL Patient CLL Society, Inc.





Maitine Rivera
Susan Smith
CLL Patients and
Co-Facilitators
CLL Support Group
Houston

To register: https://cll-houston.questionpro.com

Refreshments will be provided. You are welcome to bring a guest.

Attendees are directed to use Garage 2 or 10 for parking. MDACC visitor information is summarized at the link shown below:

https://www.mdanderson.org/patients-family/becoming-our-patient/getting-to-md-anderson.html

This program was made possible by grant support from AbbVie, BeiGene, Genentech, Gilead, Novartis, Janssen, Pharmacyclics, Sunesis, and TG Therapeutics.